Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06778863 · ClinicalTrials.gov registry record · Phase 1

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Clasp Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
90
Enrollment target
20
Study locations

NCT06778863 is a Phase 1 study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by Clasp Therapeutics. The registered enrollment target is 90 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06778863, a Phase 1 study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by Clasp Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
90 participants
Enrollment target
20
Study locations

Study Summary

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

Conditions Studied

Breast Cancer Prostate Cancer Lung Cancer Ovarian Cancer Advanced Solid Tumor Head and Neck Squamous Cell Carcinoma Pancreatic Adenocarcinoma Metastatic Solid Tumor Colorectal Adenocarcinoma Unresectable Solid Tumor

Interventions

  • DRUG CLSP-1025

Study Locations (20)

California

  • USC - Norris Comprehensive Cancer Center - Los Angeles
  • University of California Davis Comprehensive Cancer Center - Sacramento
  • University of California San Francisco - San Francisco

Texas

  • Mary Crowley Cancer Research - Dallas
  • Baylor University Medical Center - Dallas
  • MD Anderson Cancer Center - Houston

Arizona

  • HonorHealth Research Institute - Scottsdale
  • The University of Arizona Cancer Center - Tucson

New York

  • NYU Langone Health - New York
  • Memorial Sloan Kettering Cancer Center - New York

Pennsylvania

  • Thomas Jefferson University, Sidney Kimmel Cancer Center - Philadelphia
  • Fox Chase Cancer Center - Philadelphia

Tennessee

  • Sarah Cannon Research Institute (SCRI) Oncology Partners - Nashville
  • Vanderbilt University Medical Center - Nashville

Florida

  • University of Miami - Sylvester Comprehensive Cancer Center - Miami

Illinois

  • The University of Chicago Comprehensive Cancer Center - Chicago

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-02-28
Est. Completion 2028-06
Phase Phase 1

Sponsor

Clasp Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06778863

The ClinicalTrials.gov registry entry for NCT06778863 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Clasp Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which CLSP-1025 is the first listed.

NCT06778863 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Texas, Arizona.

Frequently Asked Questions

What is clinical trial NCT06778863 about?

NCT06778863 is a clinical study titled "A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation". Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

What is the current status of trial NCT06778863?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2025-02-28. Estimated completion is 2028-06.

What conditions does trial NCT06778863 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer, Advanced Solid Tumor.

What interventions are being tested in trial NCT06778863?

The interventions under investigation include: CLSP-1025 (DRUG).

Who is sponsoring clinical trial NCT06778863?

This trial is sponsored by Clasp Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06778863 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Prostate Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.